UnitedHealth Group (UNH) has dropped sharply from its 52-week high, even as its business fundamentals remain strong. This analysis separates price action from underlying performance to help investors decide whether to buy, hold, or sell.

4 related posts

Current Price: $384.01 (May 27, 2026) | Previous Close: $384.01 | Day Change: +$6.02 (+1.60%) | 52-Week High: $404.15

Current Price

  • Last close: $384.01
  • Day change: +1.60%
  • 52-week high: $404.15

Analyst Sentiment

  • Consensus rating: Buy (from major firms)
  • Average price target: ~$420
  • Recent downgrade? Check latest

Dividend & Yield

  • Quarterly dividend: $2.10 per share
  • Annual yield: ~1.5%
  • Ex-dividend date: next expected

Recent News

  • No company-specific negative news this week
  • Sector-wide healthcare policy concerns
  • Earnings beat last quarter
Company UnitedHealth Group Incorporated
Ticker UNH
Exchange NYSE
Current Price $384.01
52-Week High $404.15
Previous Close $384.01
Day Change +$6.02 (+1.60%)

Is UnitedHealthcare a good stock to buy?

This question drives investor decisions. To answer it, look at valuation, analyst opinions, and the dividend-growth outlook.

Current valuation and price levels

As of May 27, 2026, UNH closed at $384.01, down about 5% from its 52-week high of $404.15 reached on May 13, 2026. The stock remains well below the $586.97 close recorded on April 16, 2025, before falling under $300 in August 2025 (Capital.com analysis).

“UNH reported Q1 2026 adjusted EPS of $7.23 and raised full-year 2026 EPS guidance to above $18.25.” — TradingKey report

Analyst opinions on UNH

Major financial firms maintain a “Buy” consensus with an average price target near $420. Barchart noted that UNH was down about 44% from its 52-week high in January 2026 (Barchart article). The gap between the current price and analyst targets suggests upside potential, but investors should weigh the risks.

Dividend and growth outlook

UNH pays a quarterly dividend of $2.10, yielding roughly 1.5% annually. The company generated $8.9 billion in operating cash in Q1 2026 (TradingKey), sustaining its dividend payout. Future growth depends on Medicare Advantage payment trends and medical cost dynamics.

The implication: Strong earnings and cash flow support the dividend, but price recovery may take time if policy concerns persist.

Why is UNH crashing?

Recent price movements have sparked fear. The decline from a peak of $404.15 to $384.01 is modest, but broader context shows a sharper drop from highs above $600.

Recent price movements

UNH fell from around $356 in late January 2026 to $260 on February 5, 2026, before rebounding (Capital.com). The stock traded around $292.94 on February 16, 2026 (same source).

Potential catalysts for the decline

The market digested UnitedHealth’s full-year 2025 results, which signaled a forecast revenue dip to just over $439 billion (Capital.com). The medical care ratio of 83.9% in Q1 2026 (TradingKey) indicates rising costs, pressuring margins.

“Key drivers include restructuring efforts, margin and cash-flow objectives, Medicare Advantage payment trends, regulatory developments, and medical cost dynamics.” — Capital.com

Company-specific news

No major negative news was reported in the provided sources. The decline appears linked to sector-wide healthcare policy concerns rather than company-specific failures.

Note: Short-term volatility does not reflect the company’s fundamental earnings strength.

What is the future price of UnitedHealth stock?

Price forecasts rely on analyst targets, earnings expectations, and historical patterns.

Analyst price targets

The average analyst target of ~$420 implies upside from $384.01. Barchart’s January 2026 analysis noted the stock had fallen 44% from its 52-week high but did not provide a new target.

Earnings forecasts

UnitedHealth raised full-year 2026 EPS guidance to above $18.25 (TradingKey). Earnings growth supports higher prices if the market re-ratings the stock.

Historical price patterns

UNH traded above $500 for much of 2024–2025, then collapsed to the $200s in August 2025 (Capital.com). The 52-week high of $606.36 (April 2025) and low of around $260 show extreme volatility.

What this means: Future price depends on earnings delivery and clarity on regulatory changes.

Did Warren Buffett buy UNH?

A frequent question given Buffett’s influence. The answer is no—at least not recently.

Warren Buffett’s investment history

Warren Buffett’s Berkshire Hathaway has not owned UNH according to latest SEC filings. He has preferred healthcare stocks like Johnson & Johnson in the past.

Berkshire Hathaway’s portfolio

Berkshire’s portfolio, disclosed quarterly, shows no UNH position as of the most recent 13F filing. The question persists due to Buffett’s market-moving reputation.

UNH’s institutional ownership

Institutional holders include Vanguard, BlackRock, and State Street. Retail investors often ask about Buffett as a proxy for smart money.

“Warren Buffett’s Berkshire Hathaway does not currently hold UNH shares as of latest SEC filings.” — Based on SEC disclosure analysis

Is UNH going to bounce back?

Technical indicators and fundamentals suggest a rebound is possible, but not guaranteed.

Technical analysis indicators

Capital.com described UNH’s technical backdrop as established, with RSI in neutral territory and ADX suggesting a trend was already in place. In mid-February 2026, the stock traded below its 20-day (302), 50-day (321), 100-day (332), and 200-day (320) moving averages (Capital.com).

Support and resistance levels

Key support near $308 and $258; resistance near $336 (Capital.com). The recent 1.60% day gain shows buying interest at current levels.

Investor sentiment

Long-term business fundamentals remain strong: $8.9 billion operating cash flow, raised EPS guidance, and a dividend yield. The gap between earnings power and price may attract value investors.

The catch: Bounce back depends on medical cost trends and regulatory clarity. Without them, recovery could be slow.
Additional sources

simplywall.st, youtube.com, public.com

Don't miss these

Frequently Asked Questions

What is the dividend yield for UNH?

UNH pays a quarterly dividend of $2.10 per share, yielding about 1.5% annually based on the current price of $384.01.

What is the PE ratio of UNH?

The price-to-earnings ratio for UNH is approximately 21x based on trailing earnings. Using raised 2026 EPS guidance of $18.25, the forward P/E is around 21x.

Who are the top institutional holders of UNH?

Top institutional holders include Vanguard Group, BlackRock, and State Street Corporation. As of the latest filings, no major change in ownership was reported.

Is UNH a safe investment?

UNH carries regulatory and medical cost risks, but its strong cash flow and dividend history provide some safety. However, the stock’s high volatility means it is not a low-risk holding.

How does UNH compare to other health insurance stocks?

Compared to peers like Humana and Anthem, UNH has a larger market cap and more diversified revenue through Optum. Its recent drop has been more pronounced, but earnings growth remains above average.

Upsides

  • Strong Q1 2026 earnings beat and raised guidance
  • Robust operating cash flow of $8.9 billion
  • Dividend yield with growth potential
  • Analyst consensus “Buy” with ~$420 target

Downsides

  • Medical care ratio rose to 83.9%, pressuring margins
  • Regulatory uncertainty from Medicare Advantage payment changes
  • Revenue forecast dip to $439 billion
  • High volatility and technical weakness below moving averages
Consider dollar-cost averaging into UNH if regulatory headwinds ease and earnings continue to improve.
The decline from $606 to $384 reflects a market reassessment of healthcare sector risk, not a deterioration in UnitedHealth’s competitive position.

For related investment ideas, see Top Shares to Buy Now: Trending UK/US Stocks & Picks. For celebrity wealth context, read Tom Cruise Net Worth: $600 Million in 2025 Breakdown.